Mr. Donald J. McCaffrey

• 
  www.newswire.ca/en/releases/archive/June2008/19/c6074.h - [Cached Version]
  Published on: 6/19/2008    Last Visited: 6/20/2008  

  RVX-208," said Donald J. McCaffrey, President & CEO of Resverlogix."Our

• 
  www.newswire.ca/en/releases/archive/October2009/16/c741 - [Cached Version]
  Published on: 10/17/2009    Last Visited: 10/17/2009  

  "We have made a significant advancement in our clinical trial plans due to the successful results in our most recent Phase 1b/2a clinical trial," said Donald J. McCaffrey, President and CEO of Resverlogix. "We have now been able to initiate Phase 2 Pilot IVUS study activities. For the first time we will now be able to assess RVX-208 effects on actual atherosclerosis plaque within the arterial wall of the heart vessels. We are performing this study in the acute coronary syndrome population which is one of the prioritized patients groups. This is a significant milestone for Resverlogix because it will provide the Company with important coronary plaque data in late 2010. An additional benefit of conducting these two studies in parallel is that we potentially accelerate 2 years of development time, which could enable the product to reach the market sooner," added McCaffrey.

• 
  www.crmz.com/Report/ReportPreview.asp?BusinessId=746454 - [Cached Version]
  Published on: 6/15/2008    Last Visited: 6/15/2008  

  Donald J. McCaffrey
  President, Chief Executive Officer, Secretary, Director
  Resverlogix Corp.

• 
  www.marketwire.com/mw/release_html_b1?release_id=236414 - [Cached Version]
  Published on: 4/9/2007    Last Visited: 4/10/2007  

  The teleconference/webcast will provide securities analysts, shareholders, media and other key stakeholders the opportunity to hear from Donald McCaffrey, President and CEO, who will provide a corporate overview of the emerging dynamics of the atherosclerosis marketplace.Additionally, Mr. McCaffrey will discuss how Resverlogix's key technology, NexVasTM PR, is clearly differentiated and well positioned to address the enormous unmet medical need in this important therapeutic segment.Details of the ongoing strategic analysis with UBS Securities will not be discussed.
  
  The webcast can be accessed at:

• 
  www.newswire.ca/en/releases/archive/August2009/25/c7399 - [Cached Version]
  Published on: 8/25/2009    Last Visited: 8/25/2009  

  Resverlogix," stated Donald J. McCaffrey, President & CEO of Resverlogix. "There is an enormous unmet medical need in treating atherosclerosis and cardiovascular disease and the ApoA-I increases achieved by RVX-208 may just do that. We expect to update shareholders with further details of these activities later this year," added McCaffrey. In addition to successfully completing the Phase 1b/2a trial, Resverlogix

• 
  www.biospace.com/news_story.aspx?NewsEntityId=153976&So - [Cached Version]
  Published on: 8/25/2009    Last Visited: 8/26/2009  

  "Showing in the Phase 1b/2a trial that we met the primary endpoint of increasing plasma ApoA-I in a safe and tolerable way is a huge milestone for Resverlogix," stated Donald J. McCaffrey, President CEO of Resverlogix. "There is an enormous unmet medical need in treating atherosclerosis and cardiovascular disease and the ApoA-I increases achieved by RVX-208 may just do that. We expect to update shareholders with further details of these activities later this year," added McCaffrey.

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/w - [Cached Version]
  Published on: 11/29/2007    Last Visited: 12/4/2007  

  technology," stated Mr. Donald McCaffrey, President, CEO & Co-Founder of

• 
  www.newswire.ca/en/releases/archive/October2008/07/c399 - [Cached Version]
  Published on: 10/8/2008    Last Visited: 10/8/2008  

  atherosclerosis study," said Mr. Donald J. McCaffrey, President and CEO of Resverlogix.
  ...
  Donald McCaffrey, President & CEO, Resverlogix Corp., Phone: (403) 254-9252, Email: Don@resverlogix.com; Website: www.resverlogix.com

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/w - [Cached Version]
  Published on: 10/21/2008    Last Visited: 10/21/2008  

  Donald J. McCaffrey, President and CEO of Resverlogix stated, "We are

• 
  www.newswire.ca/en/releases/archive/October2008/15/c596 - [Cached Version]
  Published on: 10/16/2008    Last Visited: 10/16/2008  

  Donald McCaffrey, President and CEO of Resverlogix stated, "The economic

Page:  1 2 3 4 5